- May 07, 2026
International Desk | PNN
The rapidly developed mRNA-based COVID-19 vaccines that were widely used during the global pandemic are now showing promise in cancer treatment. Recent research indicates that these vaccines not only protect against COVID-19 but may also help the immune system recognize and attack cancer tumors.
Studies conducted on mice and analyses of medical records of cancer patients revealed surprising results. Patients who received the COVID-19 vaccine and later underwent cancer immunotherapy survived longer compared to those who were not vaccinated, who had higher mortality rates.
Researchers from the University of Florida and MD Anderson Cancer Center in Texas presented these findings at the European Society for Medical Oncology Congress in Berlin this week. The study has been published in the prestigious journal Nature.
Unlike traditional vaccines, mRNA vaccines work by delivering a small genetic code called “messenger RNA” (mRNA) directly into the body. This RNA instructs cells to produce a protein that resembles the virus, prompting the immune system to recognize it and build protection.
The study found that vaccinated patients who underwent immunotherapy lived longer, particularly those with “cold” tumors that are usually difficult for the immune system to detect. This suggests that the mRNA vaccine may prime the immune system, enabling it to better identify and attack resistant cancers.
For instance, among 43 melanoma (skin cancer) patients who were vaccinated, survival exceeded three years, whereas unvaccinated patients survived an average of only two years.
Although these findings are preliminary, if confirmed in future clinical trials, they could revolutionize cancer treatment. Researchers suggest that mRNA vaccines may enhance the body’s ability to fight tumors, opening a new avenue for cancer therapy.
Elias Sayour, a pediatric oncologist at the University of Florida, stated, “This vaccine reprograms the immune response and could serve as a universal cancer vaccine applicable to all cancer patients.”
If validated in Phase 3 clinical trials, these findings could represent a fundamental shift in cancer care.
Additionally, experiments in mice demonstrated that direct application of mRNA vaccines to tumors activates dendritic cells (a type of white blood cell), making them more alert to the presence of tumors and ultimately helping the immune system attack cancer cells.
This research represents a significant step forward in cancer therapy, though further studies and trials are still needed to confirm its effectiveness.
